| Summary: | Kamil Janeczek,1 Agnieszka Kaczyńska,1 Andrzej Emeryk,1 Cemal Cingi2 1Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Lublin, Poland; 2Department of Otorhinolaryngology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, TurkeyCorrespondence: Kamil Janeczek, Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Prof. A. Gębali 6, Lublin, 20-093, Poland, Tel +48817185477, Email kamil.janeczek@umlub.plAbstract: Bacterial lysates (BLs) are mixtures of bacterial antigens that have been used for many decades to minimize the risk of recurrent respiratory tract infections in both pediatric and adult populations. Research on the use of BLs is also conducted in allergology. Biomedical databases were searched for articles on the use of BLs in the treatment of allergic rhinitis (AR). After rejecting ineligible articles, six remaining reports were reviewed. Based on this review, it can be concluded that adding BL to standard therapy for seasonal or perennial AR reduces the severity of nasal symptoms and the need for antiallergic medications in both children and adults. Concurrently, these formulations have a high safety profile. An analysis of studies shows that the first effects of BLs therapy appear at the earliest 2– 6 weeks after the start of treatment and persist at least 3 months after treatment.Keywords: bacterial lysate, allergic rhinitis, immunostimulation, treatment
|
|---|